BMO Capital Downgrades Chemours to Underperform, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst John McNulty downgraded Chemours (NYSE:CC) from Outperform to Underperform and significantly reduced the price target from $45 to $19, indicating a bearish outlook on the stock.
March 01, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chemours was downgraded by BMO Capital from Outperform to Underperform, with a price target reduction from $45 to $19.
The downgrade from Outperform to Underperform by a major analyst, along with a more than 50% reduction in the price target, suggests a bearish outlook on Chemours. This is likely due to underlying challenges or anticipated negative performance that could impact the stock price negatively in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100